Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Biofrontera Inc
BFRI
Healthcare
Biotechnology
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial...
skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:BFRI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 31, 2024 1:50pm
BFRI....those support level got whacked
Now support is at $1.17
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 31, 2024 1:33pm
BFRI.... Crucial support at $1.55
has to hold and rally or next support is $1.45 Me no position....scalped the maddapakka all the way from $1.14 to $2 LoL
Promino Nutritional Sciences Inc. Provides Shareholder Progress Report
posted Dec 14, 2024 9:00am by
Promino Nutritional Sciences Inc.
-
|
Promino Nutritional Science's rejuvenate muscle activator, delivers the equivalent of 40 grams of whey protein isolate for just 3.6 grams of the company’s product. That was just one of the highlights in the company’s update to investors covering a transformational period for the company as new management resurrects sales with an eye on the RTD market in 2025 ...read more
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 31, 2024 11:29am
BFRI..... I smell a financing
Be careful
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 9:04am
Biofrontera Inc. (NASDAQ:BFRI): Significant Cost Savings and
https://beyondspx.com/2024/08/02/biofrontera-inc-nasdaqbfri-significant-cost-savings-and-financing-provide-path-to-profitability/
(282)
•••
whytestocks
X
Post by
whytestocks
on Feb 05, 2024 5:30pm
Biofrontera Inc. Announces FDA Filing of Supplemental New Dr
Just In: $BFRI Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per UseFDA has set a target action date of October 4, 2024 sNDA
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 30, 2022 2:09pm
New Press Release - Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmark’s 11th Annual Discovery One-on-One Investor...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 28, 2022 11:05am
New Press Release - BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Wednesday...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 21, 2022 8:49am
New Press Release - Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clinical study to...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2022 8:45am
New Press Release - Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time todayWOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and nine months...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 10, 2022 11:53am
New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 08, 2022 4:45pm
New Press Release - Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the exercise in full of options to purchase 2,623,365 ordinary shares of Biofrontera AG. These options...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2022 8:55am
New Press Release - Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
Sets company up to realize full commercial potential in fast growing U.S. marketSupports mutually beneficial interests between Biofrontera Inc and Biofrontera AGWOBURN, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 24, 2022 7:45am
New Press Release - Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately. Mr. Leffler is an...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 20, 2022 11:40am
New Press Release - Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 18, 2022 10:30am
New Press Release - Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
Four Posters Highlighting Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be PresentedWOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products...
read article.
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.